A Phase 1 Study of Concurrent Neoadjuvant Pembrolizumab Plus Chemoradiation Followed by Consolidation Pembrolizumab in Patients With Resectable Stage IIIA NSCLC

INTRODUCTION: Evidence supports the addition of immunotherapy to definitive chemoradiation for unresectable stage IIIA NSCLC. Adding pembrolizumab to neoadjuvant chemoradiation in patients with resectable stage IIIA NSCLC requires study for safety and feasibility. METHODS: Patients with resectable s...

Descripción completa

Detalles Bibliográficos
Autores principales: Lemmon, Christopher A., Videtic, Gregory M.M., Murthy, Sudish, Stephans, Kevin L., Shapiro, Marc, Ahmad, Usman, Raymond, Daniel, Velcheti, Vamsidhar, Bribriesco, Alejandro, Jia, Xuefei, Stevenson, James, Pennell, Nathan A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257414/
https://www.ncbi.nlm.nih.gov/pubmed/35815318
http://dx.doi.org/10.1016/j.jtocrr.2022.100359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257414/
https://www.ncbi.nlm.nih.gov/pubmed/35815318
http://dx.doi.org/10.1016/j.jtocrr.2022.100359

Ejemplares similares